• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

RCT Results: What is the Optimal Timing for Dinoprostone Prior to Office Hysteroscopy?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Evidence regarding prostaglandin use (e.g., misoprostol or dinoprostone) for pain relief in the setting of office hysteroscopy is conflicting
    • Lack of consistency may be due to different dosing intervals
  • Rund et al. (Journal of Minimally Invasive Gynecology, 2021) sought to determine the optimal timing of vaginal dinoprostone administration before office hysteroscopy in nulliparous women

METHODS:

  • Randomized, double-blinded trial
  • Participants
    • Nulliparous
    • Undergoing office hysteroscopy
  • Interventions
    • Long interval dinoprostone
      • 3 mg administered vaginally 12 hours before hysteroscopy
    • Short interval dinoprostone
      • 3 mg administered vaginally 3 hours before hysteroscopy
  • Primary outcome
    • Pain during hysteroscopy: Measured on 100-mm visual analog scale (0=no pain; 100=worst pain imaginable)
  • Secondary outcomes
    • Ease of hysteroscope passage
    • Patient satisfaction score
    • Drug side effects

RESULTS:

  • Long interval: 90 women | short interval: 90 women
  • Long-interval dinoprostone had lower pain scores during hysteroscopy (P<0.001)
    • Long: mean (SD) pain score 36.2 (8.1)
    • Short: 51.9 (10.5)
    • Mean difference -15.7 (95% CI, -18.4 to 12.9)
  • Pain scores 30 minutes post-procedure were similar in both groups (P=0.1)
    • Long: 28.1 (9.0)
    • Short: 31.3 (18.1)
    • Mean difference -3.2 (95% CI, -7.4 to 1.0)
  • Long interval dinoprostone was associated with
    • Greater patient satisfaction (P<0.001)
    • Easier hysteroscope passage through cervical canal (P=0.003)
    • Shorter procedure duration (P<0.001)
  • Side effects were comparable in both groups

CONCLUSION:

  • Vaginal dinoprostone administration to nulliparous patients 12 hours vs 3 hours prior to office hysteroscopy reduced pain and was also associated with higher patient satisfaction, easier hysteroscope insertion, and shorter procedure duration
  • The authors suggest that while this RCT proves “the time-dependent efficacy of vaginal dinoprostone administration for relieving pain in nulliparous women” undergoing office hysteroscopy, they also advise        

Future studies should also compare dinoprostone timings in other study populations such as postmenopausal women and include comparative placebo groups to the active study groups

Learn More – Primary Sources:

Determining the Optimal Time Interval Between Vaginal Dinoprostone Administration and Diagnostic Office Hysteroscopy in Nulliparous Women: A Randomized Double-Blind Trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Pain Control During In-Office Hysteroscopy: Nitrous Oxide vs Lidocaine vs No Analgesic
Reducing Pain During Office Hysteroscopy: Voltaren vs Buscopan
Reducing Hysteroscopy Pain with Transcutaneous Nerve Stimulation  

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site